Wednesday, 18 November 2026 Independent review of faith, culture & public life About the review
Hochland Search

Science

Isomorphic Labs raises $5 billion in second mega-round in six months

Alphabet's AI drug discovery company Isomorphic Labs has raised $5 billion, six months after a $2.1 billion round, to advance its drug pipeline toward clinical trials.

Isomorphic Labs raises $5 billion in second mega-round in six months
© the-decoder.com

Isomorphic Labs, the AI drug discovery company owned by Alphabet, has raised $5 billion in a new funding round, just six months after it closed a $2.1 billion round. The company, led by Demis Hassabis, plans to use the capital to push its drug pipeline toward clinical trials.

The size and speed of the two rounds underline how much investor attention has turned to the intersection of artificial intelligence and pharmaceutical research. Isomorphic Labs has not yet brought any drug to market, and none of its candidates is approved. The new money is therefore intended to move programs from the laboratory stage closer to the human testing that must precede any approval, a step that marks the point at which a candidate's promise is measured against real patients.

The timing of the two rounds, separated by only half a year, shows how quickly the company has been able to attract new commitments. The first round of $2.1 billion was followed by a second, considerably larger raise of $5 billion, which means the company has secured a total of $7.1 billion within a single half-year period. For a firm that has not yet produced an approved medicine, that is an unusually large amount of capital to hold in reserve for research and development.

Drug development is among the most expensive and failure-prone areas of science. Bringing a single medicine from early research to approval typically takes many years and costs large sums, and a substantial share of candidates fail in clinical trials. Companies that promise to shorten the early stages of discovery with machine learning therefore attract large commitments of capital, even before they have products to show. Investors in such ventures are betting that computational methods can identify promising molecules more quickly and with fewer dead ends than traditional laboratory screening.

For Isomorphic Labs, the funding means the company can continue expanding its research and advancing its candidates without the immediate pressure of generating revenue. Its backing from Alphabet, the parent company of Google, gives it access to deep expertise in artificial intelligence, the field in which Hassabis, a former leader of Google DeepMind, has built his reputation. That connection links the young drug discovery firm to one of the largest technology groups in the world, and it helps explain why the company has been able to draw such large sums in a short time.

The main test for the company will be whether its AI-driven approach produces drug candidates that succeed in clinical trials. Until that happens, the valuation reflects expectations rather than established results. The new round signals that its backers are willing to keep funding that wager, and it sets a high bar for the company to show that its methods can deliver medicines faster and more reliably than conventional research. Whether the second mega-round translates into faster progress toward the clinic will be the central question for the company in the coming period.

3Views

Katharina Neumann

Author

Breaking News Editor

Katharina Neumann covers public affairs, politics, business, culture and daily news for Hochland. The role focuses on verification, context, and clear explanations for readers.